Company record · updated August 5, 2026
Mirum Pharma Escrow Expense Fund: 2 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs March 31, 2026 to March 31, 2026.
2observations
2source filings
2verified rows
2026-03-31most recent as-of date
Source rails for this company: N-PORT fund mark (2).
Reported by 2 filers: T. Rowe Price Health Sciences Fund, Inc., T. Rowe Price Health Sciences Portfolio.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-03-31 | price per share | 0.95 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 2201.95 / balance 2317.84 [pp] | 000109926326006593 |
| 2026-03-31 | price per share | 0.95 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 45692.23 / balance 48097.08 [pp] | 000109926326006598 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.